SAQUINAVIR

这是一项多中心开放标签研究，旨在评估 沙奎那韦软明胶胶囊制剂与其他制剂的组合 抗逆转录病毒药物沙奎那韦是一种新的抗病毒药物， 研究用于治疗人类免疫缺陷病毒（HIV）。 沙奎那韦的作用方式与另一组抗艾滋病毒药物不同 称为逆转录酶抑制剂的药物（例如，AZT、ddC、ddI D4T）。这种药物仍在开发中。该药物是给予三个 每天口服3次，但必须在进食后立即服用 才能被人体充分吸收本方案设计用于 建立沙奎那韦在高于 目前市售的硬明胶制剂可能的那些， 提供沙奎那韦与抗- 逆转录病毒药物

This is a multi-center open label study of the safety and activity of Saquinavir soft gelatin capsule formulation in combination with other antiretroviral drugs. Saquinavir is a new antiviral drug that is being studied for the treatment of human immunodeficiency virus (HIV). Saquinavir works in a different way from another group of anti-HIV medication called reverse transcriptase inhibitors (e.g., AZT, ddC, ddI and D4T). The drug is still in development. The drug is given three times a day by mouth but must be taken immediately after eating for it to have good absorption into the body. This protocol is designed to establish the safety profile of Saquinavir at higher exposures than those possible with the currently marketed hard gelatin formulation and to provide safety and activity data on combining saquinavir with anti- retroviral drugs.